Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
April 15, 2024 at 10:01 am EDT
Share
EQS Voting Rights Announcement: Marinomed Biotech AG
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
15.04.2024 / 16:00 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Major holdings notification pursuant to Sec. 130 to 134 BörseG 2018
Wien, 15.4.2024
Overview
☐Notification made after deadline
Caution: In case of violations of major holdings notification rules, please pay attention to Section 137 BörseG 2018 (Suspension of voting rights)
1. Issuer: Marinomed Biotech AG
2. Reason for the notification: Acquisition or disposal of voting rights
3. Person subject to notification obligation Name: LLB Invest Kapitalanlagegesellschaft m.b.H. City: Wien Country: Österreich
4. Name of shareholder(s):
5. Date on which the threshold was crossed or reached: 15.4.2024
6. Total positions
% of voting rights attached to shares (7.A)
% of voting rights through financial/other instruments (7.B.1 + 7.B.2)
Total of both in % (7.A + 7.B)
Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed / reached
5,02 %
0,00 %
5,02 %
1 540 530
Position of previous notification (if applicable)
4,01 %
0,00 %
4,01 %
Details
7. Notified details of the resulting situation:
A: Voting rights attached to shares
ISIN Code
Number of voting rights
% of voting rights
Direct
(Sec 130 BörseG 2018)
Indirect
(Sec 133 BörseG 2018)
Direct
(Sec 130 BörseG 2018)
Indirect
(Sec 133 BörseG
2018)
ATMARIONOMED6
77 374
0
5,02 %
0,00 %
SUBTOTAL A
77 374
5,02 %
B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG 2018
Type of instrument
Expiration Date
Exercise Period
Number of voting
rights that may be
acquired if the
instrument is exercised
% of voting rights
SUBTOTAL B.1
B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 BörseG 2018
Type of instrument
Expiration Date
Exercise Period
Physical /
Cash Settlement
Number of
voting rights
% of voting rights
SUBTOTAL B.2
8. Information in relation to the person subject to the notification obligation:
☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
☐ Full chain of controlled undertakings through which the voting rights and/or the financial/other instruments are effectively held starting with the ultimate controlling natural person or legal entity:
9. In case of proxy voting
Date of general meeting: -
Voting rights after general meeting: - is equivalent to - voting rights.
10. Sonstige Kommentare:
Die LLB Invest Kapitalanlagegesellschaft m.b.H. hält genannte Aktien als Verwaltungsgesellschaft (KAG) von vier Investmentfonds. Es gilt hinsichtlich der Zurechnung/Kontrolle die Ausnahme nach § 134 Abs 2 BörseG und § 8 TransV 2018.
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
MARINOMED BIOTECH AG 
